Is Stereotactic Body Radiotherapy Better Than Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma?

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2016 Jun 22

PMID 27325860

Citations 6

Authors

Jen-Fu Yang

Cheng-Hsiang Lo

Wen-Yen Huang

Affiliations

Soon will be listed here.

Citing Articles

Current perspectives on radiotherapy in hepatocellular carcinoma management: a comprehensive review.

Kim D, Kim J J Liver Cancer. 2024; 24(1):33-46.

PMID: 38523467 PMC: 10990664. DOI: 10.17998/jlc.2024.02.26.

Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects.

Torimura T, Iwamoto H Clin Mol Hepatol. 2020; 27(2):236-245.

PMID: 33317248 PMC: 8046626. DOI: 10.3350/cmh.2020.0204.

Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial.

Chen L, Chiou W, Lin H, Lee M, Lo Y, Huang L BMC Cancer. 2019; 19(1):275.

PMID: 30922261 PMC: 6437913. DOI: 10.1186/s12885-019-5461-3.

Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up.

Mendiratta-Lala M, Masch W, Shankar P, Hartman H, Davenport M, Schipper M Int J Radiat Oncol Biol Phys. 2018; 103(1):169-179.

PMID: 30213751 PMC: 6301102. DOI: 10.1016/j.ijrobp.2018.09.004.

Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy.

Mendiratta-Lala M, Gu E, Owen D, Cuneo K, Bazzi L, Lawrence T Int J Radiat Oncol Biol Phys. 2017; 102(4):1063-1069.

PMID: 29029891 PMC: 5826807. DOI: 10.1016/j.ijrobp.2017.08.022.

References

Huang W, Jen Y, Lee M, Chang L, Chen C, Ko K . Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012; 84(2):355-61. DOI: 10.1016/j.ijrobp.2011.11.058. View

Riaz A, Miller F, Kulik L, Nikolaidis P, Yaghmai V, Lewandowski R . Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010; 303(11):1062-9. PMC: 3117395. DOI: 10.1001/jama.2010.262. View

Wahl D, Stenmark M, Tao Y, Pollom E, Caoili E, Lawrence T . Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol. 2015; 34(5):452-9. PMC: 4872011. DOI: 10.1200/JCO.2015.61.4925. View

Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View

Price T, Perkins S, Sandrasegaran K, Henderson M, Maluccio M, Zook J . Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer. 2011; 118(12):3191-8. DOI: 10.1002/cncr.26404. View

Bruix J, Sherman M, Llovet J, Beaugrand M, Lencioni R, Burroughs A . Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35(3):421-30. DOI: 10.1016/s0168-8278(01)00130-1. View

Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs A . EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011; 55(6):1309-16. DOI: 10.1016/j.jhep.2011.03.007. View

Bujold A, Massey C, Kim J, Brierley J, Cho C, Wong R . Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013; 31(13):1631-9. DOI: 10.1200/JCO.2012.44.1659. View

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334(11):693-9. DOI: 10.1056/NEJM199603143341104. View

10.

Edeline J, Boucher E, Rolland Y, Vauleon E, Pracht M, Perrin C . Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2011; 118(1):147-56. DOI: 10.1002/cncr.26255. View